Table 3 Clinical performance of the DNA methylation biomarkers SHOX2 and SEPT9 and cytology in ascites samples
Diagnostic method | Patients | Test result | |||
|---|---|---|---|---|---|
All patients | Cancer patients | Non-cancer patients | Positivity | Specificity | |
Cytology | 283 | 134 | 149 | 26 % (35/134) | 100 % (149/149) |
Cellular SHOX2 | 283 | 134 | 149 | 11 % (15/134) | 99 % (148/149) |
Cellular SEPT9 | 283 | 134 | 149 | 18 % (24/134) | 98 % (146/149) |
Cellular SHOX2 + SEPT9 | 283 | 134 | 149 | 24 % (32/134) | 97 % (144/149) |
Cytology + cellular SHOX2 + SEPT9 | 283 | 134 | 149 | 37 % (49/134) | 97 % (144/149) |
Cell-free SHOX2 | 162 | 81 | 81 | 16 % (13/81) | 99 % (80/81) |
Cell-free SEPT9 | 162 | 81 | 81 | 23 % (19/81) | 99 % (80/81) |
Cell-free SHOX2 + SEPT9 | 162 | 81 | 81 | 31 % (25/81) | 98 % (79/81) |
Cytology + cell-free SHOX2 + SEPT9 | 162 | 81 | 81 | 43 % (35/81) | 98 % (79/81) |
Cytology + cell-free SHOX2 + SEPT9 + cellular DNA SHOX2 + SEPT9 | 162 | 81 | 81 | 47 % (38/81) | 95 % (77/81) |